share_log

Further Weakness as Suzhou MedicalSystem Technology (SHSE:603990) Drops 19% This Week, Taking Five-year Losses to 48%

Further Weakness as Suzhou MedicalSystem Technology (SHSE:603990) Drops 19% This Week, Taking Five-year Losses to 48%

苏州医疗系统科技(SHSE: 603990)本周下跌19%,使五年跌幅达到48%,进一步疲软
Simply Wall St ·  04/17 07:57

The main aim of stock picking is to find the market-beating stocks. But even the best stock picker will only win with some selections. At this point some shareholders may be questioning their investment in Suzhou MedicalSystem Technology Co., Ltd. (SHSE:603990), since the last five years saw the share price fall 49%. And we doubt long term believers are the only worried holders, since the stock price has declined 36% over the last twelve months. Shareholders have had an even rougher run lately, with the share price down 24% in the last 90 days.

选股的主要目的是找到击败市场的股票。但是,即使是最好的选股者也只能通过以下方式获胜 一些 选择。此时,一些股东可能会质疑他们对苏州医疗系统技术有限公司(SHSE: 603990)的投资,因为在过去五年中,股价下跌了49%。我们怀疑长期信徒是唯一担心的持有者,因为股价在过去十二个月中下跌了36%。股东们最近的表现更加艰难,股价在过去90天中下跌了24%。

Given the past week has been tough on shareholders, let's investigate the fundamentals and see what we can learn.

鉴于过去一周对股东来说很艰难,让我们调查一下基本面,看看我们能学到什么。

In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.

在他的文章中 格雷厄姆和多兹维尔的超级投资者 沃伦·巴菲特描述了股价如何并不总是合理地反映企业的价值。考虑市场对公司的看法发生了怎样的变化的一种不完美但简单的方法是将每股收益(EPS)的变化与股价走势进行比较。

Over five years Suzhou MedicalSystem Technology's earnings per share dropped significantly, falling to a loss, with the share price also lower. At present it's hard to make valid comparisons between EPS and the share price. But we would generally expect a lower price, given the situation.

在过去的五年中,苏州医疗系统科技的每股收益大幅下降,跌至亏损,股价也有所下降。目前,很难对每股收益和股价进行有效的比较。但是,鉴于这种情况,我们通常预计价格会更低。

The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image).

下图描述了 EPS 随着时间的推移是如何变化的(点击图片可以看到确切的值)。

earnings-per-share-growth
SHSE:603990 Earnings Per Share Growth April 16th 2024
SHSE: 603990 每股收益增长 2024 年 4 月 16 日

Dive deeper into Suzhou MedicalSystem Technology's key metrics by checking this interactive graph of Suzhou MedicalSystem Technology's earnings, revenue and cash flow.

查看这张苏州医疗系统科技收益、收入和现金流的交互式图表,深入了解苏州医疗系统的关键指标。

A Different Perspective

不同的视角

While the broader market lost about 17% in the twelve months, Suzhou MedicalSystem Technology shareholders did even worse, losing 36%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 8% over the last half decade. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. Shareholders might want to examine this detailed historical graph of past earnings, revenue and cash flow.

尽管整个市场在十二个月中下跌了约17%,但苏州医疗系统科技股东的表现甚至更糟,下跌了36%。话虽如此,在下跌的市场中,一些股票不可避免地会被超卖。关键是要密切关注基本发展。不幸的是,去年的表现可能预示着尚未解决的挑战,因为它比过去五年中8%的年化亏损还要糟糕。总的来说,长期股价疲软可能是一个坏兆头,尽管逆势投资者可能希望研究该股以期出现转机。股东们可能需要查看这张详细的过去收益、收入和现金流的历史图表。

We will like Suzhou MedicalSystem Technology better if we see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

如果我们看到一些重大的内幕收购,我们会更喜欢苏州医疗系统科技。在我们等待的同时,请查看这份免费清单,列出了最近有大量内幕收购的成长型公司。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

请注意,本文引用的市场回报反映了目前在中国交易所交易的股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发